Form 4: MaxCyte Director John Johnston Executes Option Exercises and Stock Sales Under 10b5-1 Plan

John Johnston, a director at MaxCyte, Inc., executed option exercises and stock sales on June 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 27, 2024, John Johnston, a director of MaxCyte, Inc., engaged in transactions involving the company's common stock.
• These transactions included the exercise of stock options to acquire 5,044 shares at $1.641 and 4,956 shares at $2.926.
• Following the option exercises, Johnston sold 10,000 shares of common stock at an average price of $3.99.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 19, 2023.
• After these transactions, Johnston directly owns 141,950 shares of MaxCyte common stock and holds options to purchase additional shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were pre-planned under a 10b5-1 trading plan. It doesn't necessarily indicate a positive or negative outlook on the company.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, suggesting they were planned well in advance and not based on immediate insider information.

Risks

• Director selling activity could be perceived negatively by investors, potentially putting downward pressure on the stock price.

Industry Context

Insider transactions are common and closely monitored, especially in the biotech industry. The use of a 10b5-1 plan provides a structured approach to these transactions.

Comparison to Industry Standards

• Companies like CRISPR Therapeutics and Editas Medicine also see regular Form 4 filings from their executives and directors.
• The volume and frequency of these filings are typical for publicly traded biotech companies.

Stakeholder Impact

• Shareholders may react to the news of a director selling shares, although the pre-planned nature of the transactions may mitigate concerns.
• The transactions have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates